Human Metabolome Technologies, Inc. Logo

Human Metabolome Technologies, Inc.

A leader in metabolomics, providing CE-MS analysis to support R&D in biotech, pharma, and food.

6090 | T

Overview

Corporate Details

ISIN(s):
JP3794530000
LEI:
Country:
Japan
Address:
鶴岡市覚岸寺字水上246番地2
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Human Metabolome Technologies (HMT), Inc., founded in 2003, is a biotechnology company and a global leader in metabolomics, the comprehensive analysis of metabolites. The company specializes in providing metabolome analysis services using its proprietary capillary electrophoresis mass spectrometry (CE-MS) platform. HMT delivers high-quality metabolomics data and solutions to support research and development projects for a diverse client base that includes the pharmaceutical, biotech, food production, medical, and academic sectors. Its technologies enable new opportunities for discovery in health, food, and other complex biological systems.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-02 08:33
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 23.5 KB
2025-09-22 02:30
Registration Form
確認書
Japanese 8.4 KB
2025-09-22 02:28
Annual Report
有価証券報告書-第22期(2024/07/01-2025/06/30)
Japanese 890.5 KB
2025-09-02 08:35
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 23.3 KB
2025-08-04 08:36
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 22.4 KB
2025-07-02 08:47
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 24.4 KB
2025-06-03 08:32
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 24.0 KB
2025-05-02 08:35
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 25.6 KB
2025-04-02 08:33
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 24.8 KB
2025-03-28 02:24
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 24.1 KB
2025-02-13 07:37
Report Publication Announcement
確認書
Japanese 8.4 KB
2025-02-13 07:36
Interim Report
半期報告書-第22期(2024/07/01-2025/06/30)
Japanese 170.1 KB
2024-09-24 02:13
Post-Annual General Meeting Information
臨時報告書
Japanese 22.9 KB
2024-09-24 02:06
Governance Information
内部統制報告書-第21期(2023/07/01-2024/06/30)
Japanese 22.4 KB
2024-09-24 02:06
Registration Form
確認書
Japanese 8.4 KB

Automate Your Workflow. Get a real-time feed of all Human Metabolome Technologies, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Human Metabolome Technologies, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Human Metabolome Technologies, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Mendus Logo
Developing immunotherapies using dendritic cells to prevent cancer recurrence and improve survival.
Sweden IMMU
Develops AI-driven, glasses-free 3D holographic displays for the defense sector.
United States of America N/A
MicroAd,Inc. Logo
Data-driven marketing tech providing DSP and SSP solutions for digital advertising.
Japan 9553
Microwave Chemical Co., Ltd. Logo
Innovating chemical and metal processing with an eco-friendly microwave platform.
Japan 9227
A think tank providing research, consulting, and ICT solutions to public & private sectors.
Japan 3636
Modalis Therapeutics Corporation Logo
Develops epigenome editing therapies for genetic muscular, heart, and CNS disorders.
Japan 4883
Model Solution Co., Ltd. Logo
One-stop prototyping & low-volume production for IT, electronics, and medical hardware.
South Korea 417970
Modus Therapeutics Holding AB Logo
Developing sevuparin, a polysaccharide for sepsis, septic shock, and chronic inflammation.
Sweden MODTX
Molecure S.A. Logo
Develops first-in-class small molecule drugs for oncology and inflammatory/fibrotic diseases.
Poland MOC
Mural Oncology PLC Logo
Clinical-stage company developing cytokine immunotherapies for hard-to-treat solid tumors.
Ireland MURA

Talk to a Data Expert

Have a question? We'll get back to you promptly.